Night vision and AMD

Article

Problems with night vision correlate to an increase in the risk of symptoms of both the wet and dry forms of age-related macular degeneration (AMD), according to study results published in the November issue of Ophthalmology.

Problems with night vision correlate to an increase in the risk of symptoms of both the wet and dry forms of age-related macular degeneration (AMD), according to study results published in the November issue of Ophthalmology.

Gui-shuang Ying, PhD of the Center for Preventive Ophthalmology and Biostatics, Philadelphia, US and colleagues conducted the multicentre, randomized Complications of Age-Related Macular Degeneration Prevention Trial (CAPT), which assessed night vision in a cohort study. Participants (n=1052) had >10 drusen of >125 µm and visual acuity (VA) of >20/40 bilaterally. Subjects completed a 10-item Night Vision Questionnaire (NVQ-10), after which one eye received laser treatment and the opposite eye was monitored but not treated. VA was assessed at baseline, six months and annually thereafter, for a period of up to six years. Choroidal neovascularization (CNV) and geographic atrophy (GA) were also assessed.

The mean NVQ-10 score at baseline was 70 (range: 3–100). Patients with lower NVQ-10 scores - those with the worst night vision - were more likely to lose >3 lines of VA bilaterally during follow-up, to develop GA and to suffer CNV. Following adjustment for potential influencing factors, the difference in risk levels remained statistically significant.

The team concluded that, independently of other factors, poor night vision is associated with a greater risk of losing >3 lines of VA, development of GA and incidence of CNV.

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Related Content
© 2024 MJH Life Sciences

All rights reserved.